tiprankstipranks
Evolent Health Inc. (EVH)
NYSE:EVH
US Market
EVH
Evolent Health
RESEARCH TOOLSreports
Want to see EVH full AI Analyst Report?

Evolent Health (EVH) Stock Forecast & Price Target

754 Followers
See the Price Targets and Ratings of:

EVH Analyst Ratings

Strong Buy
12Ratings
Strong Buy
9 Buy
3 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Evolent
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EVH Stock 12 Month Forecast

Average Price Target

$5.80
▲(37.44% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is $5.80 with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a 37.44% change from the last price of $4.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","3.25":"$3.25","5.5":"$5.5","7.75":"$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.4676923076923076,3.8453846153846154,4.223076923076923,4.600769230769231,4.978461538461539,5.3561538461538465,5.733846153846153,6.111538461538462,6.489230769230769,6.866923076923078,7.2446153846153845,7.622307692307692,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.298461538461538,3.506923076923077,3.715384615384615,3.9238461538461538,4.132307692307692,4.34076923076923,4.549230769230769,4.757692307692308,4.966153846153846,5.174615384615384,5.383076923076922,5.591538461538461,{"y":5.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.09,3.083076923076923,3.0761538461538462,3.069230769230769,3.062307692307692,3.0553846153846154,3.0484615384615386,3.0415384615384613,3.0346153846153845,3.0276923076923077,3.020769230769231,3.0138461538461536,3.006923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$5.80Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on EVH
John Stansel
J.P. Morgan
J.P. Morgan
$5→$6
Buy
42.18%
Upside
Assigned
08/18/26
Evolent Health price target raised to $6 from $5 at JPMorganEvolent Health price target raised to $6 from $5 at JPMorgan
TD Cowen Analyst forecast on EVH
Charles Rhyee
TD Cowen
TD Cowen
$5→$6
Buy
42.18%
Upside
Assigned
08/17/26
Charles Rhyee Reiterates Buy, Raises Price Target to $6 on Strengthened Profit Outlook and 2027 Growth Targets
Truist Financial Analyst forecast on EVH
Jailendra Singh
Truist Financial
Truist Financial
$7→$6
Hold
42.18%
Upside
Assigned
08/12/26
Truist Financial Sticks to Their Hold Rating for Evolent Health (EVH)
Citi Analyst forecast on EVH
Daniel Grosslight
Citi
Citi
$6.75→$6
Buy
42.18%
Upside
Upgraded
08/11/26
Evolent Health upgraded to Buy from Neutral at CitiEvolent Health upgraded to Buy from Neutral at Citi
Canaccord Genuity Analyst forecast on EVH
Richard Close
Canaccord Genuity
Canaccord Genuity
$7→$6
Buy
42.18%
Upside
Reiterated
08/10/26
Evolent Health price target lowered to $6 from $7 at CanaccordEvolent Health price target lowered to $6 from $7 at Canaccord
KeyBanc Analyst forecast on EVH
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
08/10/26
Analysts Conflicted on These Healthcare Names: Evolent Health (NYSE: EVH), Eli Lilly & Co (NYSE: LLY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Oppenheimer Analyst forecast on EVH
Michael Wiederhorn
Oppenheimer
Oppenheimer
$6
Buy
42.18%
Upside
Assigned
08/07/26
Oppenheimer Keeps Their Buy Rating on Evolent Health (EVH)
William Blair Analyst forecast on EVH
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Evolent Health: Improving Fundamentals, Raised Long‑Term Guidance and Strong Contract Pipeline Support Buy Rating
RBC Capital Analyst forecast on EVH
Ryan Halsted
RBC Capital
RBC Capital
$3
Hold
-28.91%
Downside
Reiterated
08/06/26
Evolent Health (EVH) Gets a Hold from RBC Capital
Needham Analyst forecast on EVH
Matthew Shea
Needham
Needham
$5
Buy
18.48%
Upside
Reiterated
08/06/26
Evolent Health: Buy Rating Reiterated as Strong Contracts and Enhanced Risk Protections Support Growth; $5 Price Target Maintained
BMO Capital Analyst forecast on EVH
Sean Dodge
BMO Capital
BMO Capital
$6
Buy
42.18%
Upside
Reiterated
08/06/26
BMO Capital Remains a Buy on Evolent Health (EVH)
BTIG Analyst forecast on EVH
David Larsen
BTIG
BTIG
$8
Buy
89.57%
Upside
Assigned
07/16/26
BTIG Remains a Buy on Evolent Health (EVH)
UBS Analyst forecast on EVH
Kevin Caliendo
UBS
UBS
$5
Buy
18.48%
Upside
Reiterated
05/08/26
Evolent Health (EVH) Gets a Buy from UBS
Stephens Analyst forecast on EVH
Jeffrey Garro
Stephens
Stephens
$7
Buy
65.88%
Upside
Reiterated
02/25/26
Evolent Health (EVH) Gets a Buy from Stephens
Citizens JMP Analyst forecast on EVH
Constantine Davides
Citizens JMP
Citizens JMP
$11→$10
Buy
136.97%
Upside
Reiterated
01/06/26
Evolent Health price target lowered to $10 from $11 at CitizensEvolent Health price target lowered to $10 from $11 at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on EVH
John Stansel
J.P. Morgan
J.P. Morgan
$5→$6
Buy
42.18%
Upside
Assigned
08/18/26
Evolent Health price target raised to $6 from $5 at JPMorganEvolent Health price target raised to $6 from $5 at JPMorgan
TD Cowen Analyst forecast on EVH
Charles Rhyee
TD Cowen
TD Cowen
$5→$6
Buy
42.18%
Upside
Assigned
08/17/26
Charles Rhyee Reiterates Buy, Raises Price Target to $6 on Strengthened Profit Outlook and 2027 Growth Targets
Truist Financial Analyst forecast on EVH
Jailendra Singh
Truist Financial
Truist Financial
$7→$6
Hold
42.18%
Upside
Assigned
08/12/26
Truist Financial Sticks to Their Hold Rating for Evolent Health (EVH)
Citi Analyst forecast on EVH
Daniel Grosslight
Citi
Citi
$6.75→$6
Buy
42.18%
Upside
Upgraded
08/11/26
Evolent Health upgraded to Buy from Neutral at CitiEvolent Health upgraded to Buy from Neutral at Citi
Canaccord Genuity Analyst forecast on EVH
Richard Close
Canaccord Genuity
Canaccord Genuity
$7→$6
Buy
42.18%
Upside
Reiterated
08/10/26
Evolent Health price target lowered to $6 from $7 at CanaccordEvolent Health price target lowered to $6 from $7 at Canaccord
KeyBanc Analyst forecast on EVH
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
08/10/26
Analysts Conflicted on These Healthcare Names: Evolent Health (NYSE: EVH), Eli Lilly & Co (NYSE: LLY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Oppenheimer Analyst forecast on EVH
Michael Wiederhorn
Oppenheimer
Oppenheimer
$6
Buy
42.18%
Upside
Assigned
08/07/26
Oppenheimer Keeps Their Buy Rating on Evolent Health (EVH)
William Blair Analyst forecast on EVH
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Evolent Health: Improving Fundamentals, Raised Long‑Term Guidance and Strong Contract Pipeline Support Buy Rating
RBC Capital Analyst forecast on EVH
Ryan Halsted
RBC Capital
RBC Capital
$3
Hold
-28.91%
Downside
Reiterated
08/06/26
Evolent Health (EVH) Gets a Hold from RBC Capital
Needham Analyst forecast on EVH
Matthew Shea
Needham
Needham
$5
Buy
18.48%
Upside
Reiterated
08/06/26
Evolent Health: Buy Rating Reiterated as Strong Contracts and Enhanced Risk Protections Support Growth; $5 Price Target Maintained
BMO Capital Analyst forecast on EVH
Sean Dodge
BMO Capital
BMO Capital
$6
Buy
42.18%
Upside
Reiterated
08/06/26
BMO Capital Remains a Buy on Evolent Health (EVH)
BTIG Analyst forecast on EVH
David Larsen
BTIG
BTIG
$8
Buy
89.57%
Upside
Assigned
07/16/26
BTIG Remains a Buy on Evolent Health (EVH)
UBS Analyst forecast on EVH
Kevin Caliendo
UBS
UBS
$5
Buy
18.48%
Upside
Reiterated
05/08/26
Evolent Health (EVH) Gets a Buy from UBS
Stephens Analyst forecast on EVH
Jeffrey Garro
Stephens
Stephens
$7
Buy
65.88%
Upside
Reiterated
02/25/26
Evolent Health (EVH) Gets a Buy from Stephens
Citizens JMP Analyst forecast on EVH
Constantine Davides
Citizens JMP
Citizens JMP
$11→$10
Buy
136.97%
Upside
Reiterated
01/06/26
Evolent Health price target lowered to $10 from $11 at CitizensEvolent Health price target lowered to $10 from $11 at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evolent Health

3 Months
Richard CloseCanaccord Genuity
Success Rate
25/47 ratings generated profit
53%
Average Return
+0.81%
Copying Richard Close's trades and holding each position for 3 Months would result in 53.19% of your transactions generating a profit, with an average return of +0.81% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
20/47 ratings generated profit
43%
Average Return
+3.66%
Copying Richard Close's trades and holding each position for 1 Year would result in 42.55% of your transactions generating a profit, with an average return of +3.66% per trade.
2 Years
Richard CloseCanaccord Genuity
Success Rate
21/47 ratings generated profit
45%
Average Return
+18.17%
Copying Richard Close's trades and holding each position for 2 Years would result in 44.68% of your transactions generating a profit, with an average return of +18.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EVH Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
2
1
1
3
Buy
8
11
9
12
9
Hold
3
3
4
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
16
14
18
18
In the current month, EVH has received 12 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. EVH average Analyst price target in the past 3 months is 5.80.
Each month's total comprises the sum of three months' worth of ratings.

EVH Financial Forecast

EVH Earnings Forecast

Next quarter’s earnings estimate for EVH is $0.06 with a range of $0.01 to $0.10. The previous quarter’s EPS was $0.02. EVH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.
Next quarter’s earnings estimate for EVH is $0.06 with a range of $0.01 to $0.10. The previous quarter’s EPS was $0.02. EVH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.

EVH Sales Forecast

Next quarter’s sales forecast for EVH is $728.57M with a range of $686.91M to $754.70M. The previous quarter’s sales results were $652.52M. EVH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.
Next quarter’s sales forecast for EVH is $728.57M with a range of $686.91M to $754.70M. The previous quarter’s sales results were $652.52M. EVH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.

EVH Stock Forecast FAQ

What is EVH’s average 12-month price target, according to analysts?
Based on analyst ratings, Evolent Health Inc.’s 12-month average price target is 5.80.
    What is EVH’s upside potential, based on the analysts’ average price target?
    Evolent Health Inc. has 37.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EVH a Buy, Sell or Hold?
          Evolent Health Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Evolent Health Inc.’s price target?
            The average price target for Evolent Health Inc. is 5.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 37.44% Increase from the current price of $4.22.
              What do analysts say about Evolent Health Inc.?
              Evolent Health Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of EVH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.